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A study was undertaken to compare the efficacy of plasmid constructs encoding human IFN-2 and IFN- and macaque
IFN- against herpes simplex virus type 1 in transfected cells. All type I IFN transgenes significantly reduced viral titers in
transfected cells by 3 logs. Human IFN-2-transfected cells produced significantly more IFN (2274 pg/ml) in comparison to
IFN--transfected cells (134–165 pg/ml). Viral lytic gene transcript and viral protein levels were lower in IFN-- versus
IFN-2-transfected cells, which coincided with elevated PKR and OAS transcript levels and increased total STAT1 and
phosphorylated STAT1 (Y701) protein levels in the IFN--transfected cells. Although comparable viral titers were recovered
in IFN-2 and IFN- plasmid-transfected cells, IFN-2 plasmid-transfected cells exhibited significantly more cytopathic effect
compared to the IFN- transgene-transfected cells. In addition, IFN-2 transgene-transfected, infected cells displayed a cell
cycle profile similar to that of vector-transfected, infected cells, whereas IFN- plasmid-transfected cells displayed a profile
similar to uninfected control. Collectively, the results indicate that human IFN- is superior to IFN-2 in antagonizing herpes
simplex virus type 1 infection. © 2001 Academic Press
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INTRODUCTION
Type I interferon (IFN) was first recognized for its
properties against viral replication (Isaaks and Linden-
mann, 1957). In addition to the direct antiviral effect, type
I IFNs exert a wide variety of other activities, including
the induction or suppression of cytokines (Khademi et al.,
2000; Taylor and Grossberg, 1998), the stimulation of
effector cells (De Maeyer and De Maeyer-Guignard,
1998; Marrack et al., 1999), and anti-proliferative (Peli-
cano and Chelbi-Alix, 1998) and proapoptotic effects
(Tanaka et al., 1998; Balachandran et al., 2000). Due to
these pleiotropic effects, recombinant interferons are
used to treat a variety of diseases, including cancer
(Pelicano and Chelbi-Alix, 1998), viral hepatitis (Zein,
1998), and multiple sclerosis (IFNB Multiple Sclerosis
Study Group, 1993; PRISMS Study Group, 1998). The
antiviral properties associated with type I IFN subtypes
are induced after the interaction with the extracellular
type I receptor domain followed by specific intracellular
signaling pathways that lead to the selective expression
of genes whose products interfere with viral replication
(Foster and Finter, 1998). Two prominent IFN-regulated
gene products include the dsRNA-activated protein ki-
nase R (PKR) and the 2,5-oligoadenylate synthetase
(OAS). PKR interferes with protein synthesis by phos-
phorylating the translational initiation factor eIF2 and by
modulating STAT1 signaling (Wong et al., 1997). OAS
uses ATP as a substrate to synthesize 2,5-oligoadeny-
late, which activates RNase L and degrades mRNA
(Samuel, 1991; Vilcek and Sen, 1996) as well as exerting
proapoptotic properties (Castelli et al., 1998). Other stud-
ies have shown type I IFNs to interfere with virion as-
sembly in vesicular stomatitis virus (VSV) (Maheshwari
and Friedman, 1980) and herpes simplex virus type 1
(HSV-1) (Chatterjee et al., 1985; Munoz and Carrasco,
1984) infections, resulting in the release of defective
progeny. The multitude of different IFN-induced effector
cascades act in concert during a viral infection such that
an antiviral state is created in uninfected cells while
infected cells undergo apoptosis, generate defective par-
ticles, or repress viral gene expression. These events
along with the adaptive immune response can effectively
clear the infection.
The predominate type I antiviral IFNs include IFN-
and IFN-. Although these species bind to the same
receptor, the outcome of their potency varies widely,
depending on the biologic effect measured (Foster and
Finter, 1998; Swaminathan et al., 1992; Yeow et al., 1998).
Regarding HSV-1 infection, murine IFN- plasmid-trans-
fected cells repress viral replication to a greater extent
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than murine IFN-1 plasmid-transfected cells as deter-
mined by measuring viral titers (Cui and Carr, 2000;
Noisakran et al., 1999). The primary aim of the present
study was to compare the antiviral properties of different
human and macaque type I IFN plasmid DNA constructs.
The results show a greater antiviral effect per unit basis
by IFN-, suggesting that this type I IFN is an excellent
candidate to pursue in in vivo gene transfection studies
against HSV-1 infection.
The HSV-1 G207 was employed in the present study
due to its enhanced sensitivity to type I IFNs (Leib, 2000).
Specifically, the HSV-1 mutant G207 lacks both 34.5
gene loci. The gene product of 34.5, ICP34.5, is a
neurovirulence factor that is not essential for viral growth
in replicating cells (Chou et al., 1990). However, ICP34.5
binds to protein phosphatase 1, leading to the dephos-
phorylation of eIF-2 and enabling protein synthesis
(Samuel, 1991; Vilcek and Sen, 1996). This molecular
mechanism counteracts the protein synthesis inhibition
properties of PKR, facilitating viral replication. By employ-
ing the HSV-1 mutant, differences in antiviral efficacy
between type I IFN species could be more easily dis-
cerned.
RESULTS
Expression of type I IFN transgenes
Plasmid constructs encoding human and macaque
type I IFNs were generated. To test if these plasmid
constructs express functionally active IFN, Vero cells
were transfected with naked plasmid DNA containing
human (Hu) IFN-2, HuIFN-, or macaque (mc) IFN-
transgenes in combination with the polyamidoamine Su-
perfect. Using a reporter gene construct (pVAX contain-
ing the -galactosidase gene), less than 1% of the cells
were successfully transfected. However, transfected
cells generated a considerable amount of HuIFN-2 as
determined by bioassay and ELISA (Fig. 1). In contrast,
significantly less (P  0.01) Hu- or mcIFN- was mea-
sured in the supernatants of transfected cells in compar-
ison to HuIFN-2 (Fig. 1). Cells transfected with pVAX
vector alone did not secrete measurable IFN (Fig. 1).
Potency of HuIFN- and mcIFN- is superior to IFN-
2 against HSV-1
Since cells transfected with plasmid DNA containing
type I IFNs expressed biologically active proteins, a
study was undertaken to determine the resistance of
these cells to HSV-1 infection. Transfected cell monolay-
ers were monitored for cytopathic effect (CPE) and viral
reporter gene expression. Vector control-transfected
cells showed significant CPE and reporter gene expres-
sion 24 h p.i. (Fig. 2). In contrast, HuIFN-2-transfected
cells showed significantly less CPE and fewer cells ex-
pressing -galactosidase (Fig. 2). In comparison to
HuIFN-2, IFN- transgene-transfected cells showed
less CPE and considerably fewer cells expressing the
HSV-1 reporter gene (Fig. 2). Viral titers determined in the
supernatant of IFN transgene-transfected cells were sig-
nificantly (P  0.01) reduced in comparison to viral titers
in the supernatants of cells transfected with the vector
control (Fig. 3). Cells transfected with the IFN2 trans-
gene showed a 2-fold greater reduction in viral titer in
comparison to cells transfected with the IFN- trans-
genes. However, based on the amount of IFN produced
by the transfected cells relative to infectious viral prog-
eny, it would take between 5- and 20-fold more HuIFN-
to achieve the same level of protection compared to
IFN-. These results are consistent with a dose–re-
sponse study in which cells treated with rHuIFN- and
subsequently infected with HSV-1 showed an approxi-
FIG. 1. Transfected Vero cells secrete biologically active IFN. (A) Vero
cells were transfected with the IFN plasmid construct (1 pg DNA/cell)
and 24 h p.i. supernatant was collected and assayed for IFN by
bioassay. Data are represented as means  SEM from eight indepen-
dent experiments. ** P  0.01 comparing IFN-2 to both IFN-s. All
type I IFN-transfected cells produced significantly more biologically
active IFN in comparison to the pVAX (vector only) group, which did not
produced detectable levels of IFN. (B) Supernatants obtained from
transfected Vero cell cultures 24 h p.i. were analyzed for IFN content by
ELISA. This is a summary of two independent experiments and pre-
sented as means  SD. ** P  0.01 comparing IFN-2 to both IFN-s.
There was no detectable IFN ( or ) in the supernatants from the
pVAX-transfected group.
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FIG. 2. Cytopathic effect and viral reporter gene expression in type I IFN transgene-transfected cells. Transfected and infected monolayers were
stained with crystal violet (upper four images) 24 h p.i. to visualize cytopathic effect or stained for -galactosidase activity (lower four images) to
visualize viral gene expression. The HSV-1 mutant G207 contains a lacZ insert in the early gene (UL6). Cell nuclei were counterstained with nuclear
fast red. pVAX is the plasmid vector control. IFN-2-transfected cells showed more abundant -gal expression, suggesting stronger viral gene
expression compared to IFN--transfected cells. There was consistently 3–10 times the CPE in a given field of cells transfected with the IFN-2
transgene in comparison to cells transfected with the IFN- (human or macaque) transgene.
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mately 7-fold lower IC50 compared to cells treated with
rHuIFN-2 (Fig. 4).
HSV-1 gene expression is more efficiently reduced by
IFN- compared to IFN-2 transgenes
Transfected cells were evaluated for HSV-1 gene tran-
script expression at times p.i. Cells transfected with
IFN-2 and IFN- transgenes were found to have re-
duced immediate-early (ICP27), early (TK), and late
(VP16) viral gene expression compared to cells trans-
fected with the vector control (Fig. 5). However, there was
a more abundant expression of viral gene transcripts in
the IFN-2- compared to the IFN--transfected cells.
Specifically, the expression of ICP27 was repressed in
the IFN- samples compared to IFN-2 at both 6 and
10 h p.i. Likewise, VP16 was not detectable in the IFN-
-transfected cells at both time points, whereas expres-
sion of ICP27 and VP16 in the IFN-2-transfected cells
was clearly visible at 10 h p.i. Since standard PCR is not
a quantitative measurement, real-time PCR analysis of
viral genes in the transfected, infected Vero cells was
examined. In measuring ICP27, TK, and glycoprotein B
(gB), cells transfected with the mcIFN- or HuIFN- con-
sistently showed a greater fold reduction in viral gene
expression in comparison to HuIFN-2 (Fig. 6). Extrapo-
lating from the RT-PCR and real-time PCR results, viral
protein levels were expected to be reduced in IFN-2 or
IFN- transgene-transfected cells in comparison to plas-
mid vector controls. Western blot analysis revealed re-
duced HSV-1 proteins in IFN transgene-transfected cells
compared to plasmid vector-transfected controls (Fig. 7).
Likewise, IFN- transgenes reduced HSV-1 gB levels
more efficiently than IFN-2 transgene-transfected cells
(Table 1).
FIG. 3. Cells transfected with type I IFN transgenes are less sensitive
to HSV-1 infection compared to plasmid vector controls. Vero cell
monolayers were transfected (1 pg DNA/cell) and 24 h later infected
with HSV-1 (m.o.i. of 0.1). The viral titer in the supernatant was deter-
mined 24 h p.i. A representative of eight independent experiments is
shown. Titers were determined in triplicate and presented as means
SEM. ** P  0.01 comparing IFNs to plasmid vector control.  P 
0.01 comparing IFN-2 to both IFN-s.
FIG. 4. Type I IFNs antagonize HSV-1 replication in a dose-depen-
dent fashion. Vero cells were incubated with serial dilutions of
rHuIFN-2 and rHuIFN- for 24 h followed by infection with HSV-1
(m.o.i. of 0.1). Viral titers were determined by microtiter plaque assay
after two freeze–thaw cycles. Data are presented as means  SEM.
Four experiments were carried out for IFN- and six experiments for
IFN-2. * P  0.05 and ** P  0.01 comparing IFN- to IFN-2 at
corresponding concentrations.
FIG. 5. Type I IFN transgenes antagonize HSV-1 lytic gene expres-
sion. RNA from transfected, infected Vero cells was collected at 6 or
10 h p.i. (m.o.i. of 0.1) and used in RT-PCR assays to analyze immediate-
early (ICP27), early (TK), and late (VP16) HSV-1 gene expression. A
representative of four independent experiments is shown.
FIG. 6. Real-time PCR analysis of viral lytic gene expression in cells
transfected with type I IFN transgenes. RNA from transfected, infected
Vero cells was collected 18 h p.i. (m.o.i. of 0.5) and used in RT real-time
PCR assays to analyze viral lytic genes. Bars represent means  SD.
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HSV-1-infected cells do not undergo apoptosis
Considering the more abundant transcriptional and
translational viral products and the stronger virus-in-
duced CPE in IFN-2 compared to IFN- transgene-
transfected cells, it was surprising that the viral titers
24 h p.i. were lower in the IFN-2 than in the IFN-
transgene-transfected cells. These disparate results
might be due to enhanced apoptotic events in the IFN-2
plasmid-transfected cells subverting viral packaging in
the host cells and leading to reduced viral titers. Previ-
ous studies have found that type I IFNs are essential
mediators of apoptotic death in virally infected cells
(Tanaka et al., 1998). To investigate this possibility, trans-
fected, infected cells were evaluated for apoptosis using
propidium iodide and flow cytometry to quantitate cells in
the sub-G1/G0 phase. The results show no difference in
the sub-G1/G0 population comparing the type I IFNs (Fig.
8). Furthermore, RT-PCR for apoptotic and antiapoptotic
genes, including bax, bcl-XL, and bcl-G, and Western blot
analysis for bax and bcl-XL/S proteins did not reveal any
differences between the transgene-treated groups (data
not shown). Therefore, it is unlikely that apoptotic events
are involved in the difference in CPE comparing the type
I IFN transgenes. Interestingly, flow cytometry analysis
revealed a shift of the G1/G0 phase into the S and G2/M
phase region in all infected groups. The most profound
shift occurred in the vector control- and the IFN-2-
transfected cells, with the G1/G2 almost completely ab-
sent. However, both IFN- groups clearly showed a vis-
ible G1/G0 peak. The IFN transgene transfection itself
without infection did not alter cell cycle profiles (data not
shown). Recent studies on HSV cell cycle interference
have reported viral-induced cell cycle arrest at the junc-
tions of G0/G1, G1/S, and G2/M phases (de Bruyn Kops
and Knipe, 1988; Hobbs and DeLuca, 1999; Lomonte and
Everett, 1999). Therefore, we conclude that the almost
complete shift of plasmid vector and IFN-2 plasmid-
transfected, infected cells in the G1/G0 area to the S and
G2/M area is due to enhanced viral DNA synthesis. The
inhibitory effect on viral DNA synthesis was pronounced
in IFN- compared to IFN-2 transgene-transfected cells
and is consistent with the enhanced transcription and
translation of HSV-1 genes in the IFN-2 transgene
group. However, these results could not explain the con-
flicting data comparing viral titers to viral gene expres-
sion between the type I IFN subtypes.
IFN- suppresses viral replication over time
Some studies suggest that type I IFN induces the
production of defective virions (Maheshwari et al., 1994;
Munoz and Carrasco, 1984). Therefore, viral titers were
measured in the supernatants and in lysed monolayers
of infected cells at 24 or 48 h p.i. Significantly (P  0.01)
higher viral titers were recovered in the supernatants
and lysed monolayers comparing vector control-trans-
fected cells 24 to 48 h p.i. (Fig. 9). In contrast, significantly
lower (P  0.05) viral titers were recovered at 48 h
compared to 24 h p.i. in the IFN- transgene-transfected
and lysed monolayers. IFN-2 transgene-transfected
cells showed a similar protective effect but the differ-
ences were not significant. In addition, viral plaque for-
mation was greatly reduced in size in the transgene-
treated groups compared to the vector-transfected con-
trols. These results implicate that all three IFN subtypes
induced viral crippling such that further viral generations
were greatly impaired in their ability to successfully in-
fect neighboring cells.
TABLE 1
IFN- Transgenes Are More Effective in Repressing gB Expression
in HSV-1 Infected Cells Than the IFN-2 Transgenea
Vector control HuIFN- HuIFN-2 mcIFN-
37.4 3.4b 0.2 0.2**, 3.4 0.6 0.0 0.0**,
a Vero cells were transfected and 24 h later infected with HSV-1
(m.o.i. of 0.1). Twenty-four hours p.i. total cell protein was isolated and
subjected to polyacrylamide gel electrophoresis and Western blot anal-
ysis (15 g protein/lane) for gB.
b The numbers represent the gB yield expressed in terms of inte-
grated volume in pixels as determined using imaging software. Data
are presented as the means  SEM from four independent experi-
ments.
** P  0.01 comparing IFN-2 to both IFN-s.
 P  0.01 comparing the vector control with all IFN transgenes.
FIG. 7. IFN- inhibits viral protein synthesis more efficiently than
IFN-2. Total cell lysates (15 g protein/lane) were electrophoresed on
7.5% polyacrylamide gels. The protein was subsequently transferred
onto nitrocellulose membranes and probed for HSV-1 antigen using a
polyclonal anti-HSV Ab. Labeled antigen was detected by chemilumi-
nescence. A representative of five independent experiments is shown.
241HUMAN AND MACAQUE TYPE I IFN TRANSGENES AND HSV-1
PKR and OAS mRNA levels and STAT1 protein levels
are elevated in Hu- and mcIFN- compared to
HuIFN-2 transfection
It is well established that IFN induces antiviral genes,
including PKR and OAS, via the Jak/STAT pathway (Stark
et al., 1998). Since PKR and OAS are known to interfere
with viral replication (Samuel, 1991), they are possible
candidates to explain the difference in viral transcript
and protein expression levels between the IFN- and the
IFN2 transgene-transfected cells. Therefore, PKR and
OAS transcript levels were measured by RT-PCR (Fig. 10).
All IFN transgene-treated samples increased both PKR
and OAS transcript levels compared to the vector-trans-
fected and nontransfected control cells (Table 2). Both
IFN- transgene-transfected cells enhanced PKR and
OAS transcript expression compared to IFN-2 but the
difference did not reach significance. Similar to PKR and
OAS expression, all type I IFN transgenes elicited a
significant (P  0.05) up regulation of total STAT1 (p91/
p84). STAT1 expression in the IFN- transgene-trans-
fected cells was significantly (P  0.05) enhanced com-
pared to HuIFN-2 transgene-transfected cells. Further-
more, phospho-STAT1 (Y701) proteins were up regulated
the most in mcIFN- followed by HuIFN- and were
barely detectable in the HuIFN-2-transfected cells (Ta-
ble 2; Fig. 10).
FIG. 8. IFN- transgenes subvert viral DNA synthesis in infected host cells. Vero cells were transfected and 24 h later infected with HSV-1 (m.o.i.
of 1). Twenty-four hours p.i., cells were harvested, fixed, and subsequently stained with propidium iodide. Twenty thousand events were analyzed per
group. An accumulation of cells in the S and G2/M phases is larger in the vector control- and IFN-2- than in the human or macaque IFN-
transgene-transfected cells, suggesting an enhanced viral DNA synthesis. A representative of two experiments with identical outcomes is shown.
FIG. 9. Comparison of viral titers 24 and 48 h postinfection in the
supernatant and in lysed monolayers. Vero cells were transfected with
IFN transgenes (1 pg/cell) and, 24 h later, infected with HSV-1 (m.o.i. of
0.1). The supernatants or cell lysates (from monolayers freeze–thawed
three times) were collected at 24 or 48 h p.i. Viral titers were deter-
mined by plaque assay. Data are presented as means  SEM, n  3.
** P  0.01 and * P  0.05 comparing viral titers between lysates and
supernatants at 24 versus 48 h p.i.
FIG. 10. IFN- transgenes are more potent inducers of PKR and OAS
mRNA and STAT1 proteins compared to the IFN-2 transgene. Vero
cells were transfected with IFN transgene constructs and 24 h later
infected with HSV-1 (m.o.i. of 0.1). Twenty-four hours p.i. RNA or total
cell protein was isolated and analyzed by RT-PCR for PKR and OAS and
by Western blot analysis for total STAT1 and phospho-STAT1 (Y701). A
representative of four independent experiments is shown.
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DISCUSSION
HuIFN-2, HuIFN-, and mcIFN- plasmid constructs
were generated and tested for their antiviral potency.
Cells transfected with these IFN plasmid constructs pro-
duced biologically active IFN. In tissue culture transfec-
tion experiments, IFN-2 levels were 10- to 60-fold
higher than those of IFN-. Since the same plasmid
backbone was used to clone in nearly identical-length
IFN transgenes, the difference in IFN synthesis could not
be due to a difference in plasmid size that might influ-
ence transfection efficiency. However, glycosylation of
the IFN- protein (Vilcek and Sen, 1996) is an important
factor for the solubility, stability, and activity of this cyto-
kine (Karpusas et al., 1998). In contrast, the IFN-2 pro-
tein does not exhibit glycosylation sites (Vilcek and Sen,
1996). The glycosylation process in transfected Vero
cells could therefore cause the difference in the IFN-
and IFN-2 protein generated.
IFN- was found to have a greater effect in inhibiting
HSV-1 replication compared to IFN-2 in a dose–re-
sponse study. The stronger antiviral effect of IFN- com-
pared to IFN-2 was also demonstrated by determining
viral transcript levels of three representative lytic genes,
analyzing HSV protein levels, and determining DNA con-
tent of infected cells. A previous study reported a de-
layed HSV-1 gene expression in IFN-pretreated cells,
demonstrating that the interference occurs at early
stages of HSV-1 replication (Altinkilic and Brandner,
1988; Gloger and Panet, 1984; Oberman and Panet,
1988). Similar to our findings, another group reported that
IFN- inhibits replication in 13 different HSV-1 strains
tested to a greater extent than IFN- or IFN- (Arao et al.,
1997). However, this study did not investigate any under-
lying mechanisms associated with the differences ob-
served and did not use IFN DNA transgenes.
Transfection of Vero cells with different type I IFN
transgenes up regulated total STAT1 and phospho-STAT1
(Y701) (STAT1) along with PKR and OAS transcript lev-
els. Furthermore, STAT1 protein levels were expressed
significantly more strongly in both IFN--transfected
groups compared to IFN2 transgene-transfected cells
with the same relationship obtained for PKR and OAS
transcript levels. Consistent with these results, a recent
publication reported that rIFN- induces STAT1 phos-
phorylation to a greater extent than rIFN- in human
myocardial fibroblasts as a result of Jak1 kinase activa-
tion (Grumbach et al., 1999). In addition, it is well estab-
lished that the up regulation of the Jak/STAT pathway
elicits IFN-inducible molecules, including PKR and OAS,
which have potent antiviral effects (Samuel, 1991). PKR,
in turn, has been suggested to nonenzymatically associ-
ate with STAT1 thus preventing STAT1 interaction with
DNA binding regions (Wong et al., 1997). Therefore, ele-
vated PKR and STAT1 levels may act in concert to modify
the cellular machinery against viral transcription. Khabar
et al. demonstrated that in the absence of PKR HSV-1
replication is greatly enhanced, suggesting that PKR-
mediated antiviral mechanisms are of great importance
in the defense against HSV-1 infections (Khabar et al.,
2000). In accordance with elevated PKR and OAS levels
in the IFN- compared to the IFN-2 transgene-trans-
fected cells, significantly less viral lytic gene transcripts
and viral protein expression were detected. Since viral
gene expression in IFN--transfected cells was re-
pressed, lower HSV-1 titers in this group compared to
IFN-2-transfected cells was expected. However, it was
surprising that a twofold increase in HSV-1 titer was
detected in the IFN- compared to the IFN-2 transgene-
transfected groups. Taken together, the data suggest that
in addition to the PKR and OAS system, other antiviral
mechanisms are involved. In a time-course experiment,
viral titers in the supernatants and in cell lysates of the
vector-transfected controls were elevated comparing 24
to 48 h p.i. This outcome was expected, since unim-
peded viral replication is complete within 18 to 24 h,
allowing sufficient time for at least two rounds of repli-
cation at the 48-h time point. Yet, unexpectedly, viral titers
were reduced comparing 24 to 48 h p.i. within the IFN-
TABLE 2
IFN- Transgenes Are More Potent Inducers of PKR and OAS mRNA and STAT1 Proteins Compared to the IFN-2 Transgenea
No treatment Vector control HuIFN- HuIFN-2 mcIFN-
PKR 0.23 0.08b 0.25 0.04 0.83 0.19 0.55 0.09 1.12 0.3*,
OAS 0.32 0.06 0.25 0.09 0.72 0.13 0.66 0.13 1.13 .21*,
STAT1
p91 6.1  0.8 7.5  1.3 24.4  1.1**, 18.8  1.0 21.8  0.9*,
p84 1.1  0.6 2.1  0.6 18.2  2.5**, 11.5  1.6 16.5  1.0**,
a Vero cells were transfected and 24 h later infected with HSV-1 (m.o.i. of 0.1). Twenty-four hours p.i. RNA or total cell protein was isolated and
analyzed by RT-PCR for PKR and OAS or by Western blot analysis for STAT1.
b The numbers represent the RT-PCR or Western blot product yield expressed in terms of integrated volume in pixels as determined using imaging
software. Data are presented as the means  SEM from four or five independent experiments.
** P  0.01 and * P  0.05 comparing IFN-2 to both IFN-s.
 P  0.01 comparing the vector control and no treatment with all IFN transgenes.
243HUMAN AND MACAQUE TYPE I IFN TRANSGENES AND HSV-1
transgene-transfected group. Furthermore, viral plaque
size was greatly reduced in all IFN transgene-trans-
fected groups compared to the vector control. It is tempt-
ing to speculate that these results suggest that defective
and noninfectious viral progeny may be generated. Con-
sistent with this hypothesis are other reports suggesting
that IFN-treated cells generate noninfectious virions
(Chatterjee et al., 1985; Chatterjee and Whitley, 1989;
Munoz and Carrasco, 1984). Specifically, it has been
demonstrated that crippled HSV-1 particles are produced
by a disturbance of glycoprotein D localized to the cell
membrane as a result of glycoprotein trapping in the
Golgi apparatus (Maheshwari et al., 1994). Glycoprotein
D is essential for HSV-1 infectivity (Campadelli-Fiume et
al., 2000). Considering the more abundant expression of
viral genes in the IFN-2 transgene-transfected cells but
lower viral titers compared to IFN- transgene-trans-
fected cells, viral crippling seems to be another impor-
tant antiviral mechanism of type I IFNs. This viral crip-
pling effect does not completely block viral replication,
but the speed and efficiency of viral replication are
greatly reduced.
Recently it has been reported that a recombinant virus
that fails to express UL34 protein forms minute plaques
and replicates in titers 3 to 5 log orders of magnitude
lower than wild type (Roller et al., 2000). In this investi-
gation, the deletion virus was found to synthesize pro-
teins of all kinetic classes in normal amounts. However,
electron microscopic and biochemical analyses showed
that the morphogenesis of the deletion virus displayed
no enveloped viral particles in the cytoplasm or at the
surface of infected cells. The authors interpret these
results to suggest that the UL34 protein is essential for
efficient envelopment of capsids. Since the HSV-1 UL34
gene encodes a protein that is conserved in the alpha-
herpesviruses (Davison and Scott, 1986; Dolan et al.,
1998; Telford et al., 1992) and has sequence homology to
the UL50 protein of other herpesviruses (Bankier et al.,
1991), the reduced expression of this gene could be a
common and novel antiviral mechanism of type I IFNs
against human herpesviruses.
A potentially clinically important observation with re-
spect to IFN therapy is the diminished CPE observed in
cells transfected with IFN- compared to IFN-2 trans-
genes. Typically, in dose–response studies comparing
the efficacy of IFN subtypes, equal concentrations of
IFNs are used. In contrast, the primary aim of the present
study was to evaluate the sensitivity of cells transfected
with equivalent amounts of plasmid DNA. By employing
equivalent amounts of IFN protein, a difference in CPE
comparing IFN-2 with IFN- would not have been sur-
prising. Specifically, at equal protein concentrations of
IFN-2 and IFN-, more virus is generated in the IFN-
2-treated samples as shown in the dose–response
curves and therefore, a stronger CPE results. But at IFN
concentrations that yield similar viral titers, IFN--trans-
fected cells clearly exhibit less CPE compared to IFN-
2-transfected cells. This protective attribute should be
considered when sensitive tissues (e.g., optically clear
cornea) are involved. One possible explanation of the
difference in CPE resides within the production of viral
products. For example, high concentrations of ICP0 (in-
fected cell protein 0) and other immediate-early proteins
are toxic to cells (Wu et al., 1996). Viral lytic gene expres-
sion was elevated in IFN-2 compared to IFN- trans-
gene-transfected cells and could therefore account for
the difference in CPE. This hypothesis is supported by
the detection of equal activities of lactate dehydroge-
nase in the supernatants and in total cell lysate as a
parameter for cell death (data not shown).
In summary, IFN- transgene-transfected cells have
been found to repress HSV-1 gene expression at the
DNA, mRNA, and protein levels to a greater extent than
IFN-2 transgene-transfected cells. This effect corre-
lated with an elevation in STAT1 protein and PKR and
OAS transcript levels. Moreover, IFN- transgene-trans-
fected cells exhibit a tissue-protective effect compared to
IFN-2 transgene-transfected cells. Finally, all three IFN
subtypes interfere with the production of infectious prog-
eny. The antiviral impact of IFN- seems to be blocking
or delaying viral lytic gene and protein expression,
whereas IFN-2 antagonizes HSV-1 replication farther
downstream. In either case, this study clearly demon-
strates the antiviral nature of type I IFNs at the cellular
and subcellular levels.
MATERIALS AND METHODS
Cell lines and viruses
Propagation and experiments with green monkey kid-
ney fibroblasts (Vero cells, ATCC CCL-81; Manassas, VA)
and human laryngeal epidermoid carcinoma-derived
cells (HEp-2 cells, ATCC CCL-23) were carried out in
RPMI culture medium supplemented with 10% FBS and
antibiotic/antimycotic solution (GIBCO BRL, Gaithers-
burg, MD) at 37°C, 5% CO2, and 95% humidity.
In all experiments except the IFN bioassay, the HSV-1
mutant G207 (strain F derived), containing deletions at
both  34.5 (RL1) loci and an Escherichia coli lacZ gene
insertion inactivating the ICP6 gene (UL39) (Mineta et al.,
1995) (Medigene, Inc., San Diego, CA) was used. The
indicator virus in the IFN bioassay was encephalomyo-
carditis virus (EMCV) (a kind gift from Dr. William P.
Halford, Tulane University Medical Center, New Orleans,
LA). HSV-1 and EMCV were propagated in Vero cells and
aliquots were stored at 80°C.
Plasmid constructs
Type I interferon genes for HuIFN-2, HuIFN-, and
mcIFN- were cloned into the FDA-approved pVAX1
plasmid vector (Invitrogen, Carlsbad, CA). The vector
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contains a CMV immediate-early promoter, a bovine
growth hormone polyadenylation signal, and a kanamy-
cin-resistance gene for selection in E. coli. Restriction
sites for HuIFN-2 were PstI and XhoI, for HuIFN- KpnI
and XhoI, and for mcIFN- PstI. The plasmid constructs
were transformed into the E. coli strain INVF (Invitro-
gen) and grown in Terrific broth, containing 50 g/ml
kanamycin, followed by purification using Qiagen Maxi
kits (Qiagen, Inc., Valencia, CA). The correct IFN gene
insert was verified by sequence analysis in both direc-
tions for all three plasmid constructs. After each plasmid
isolation restriction enzyme digestion was conducted
and the products were analyzed by agarose gel electro-
phoresis.
IFN dose–response study
Vero cells were incubated in 24-well plates for 24 h
with serial dilutions of recombinant HuIFN-2 or -
(rHuIFN-2 or rHuIFN-) (PBL Biomedical Laboratories,
Brunswick, NJ) followed by infection with G207 at a
multiplicity of infection of 0.1. One hour postinfection, the
inoculum was replaced with fresh culture medium.
Twenty-four hours p.i. cells were lysed by two freeze–
thaw cycles and viral titers were determined in duplicate
by microtiter plate plaque assay using Vero cells. Plates
were stained with crystal violet and plaques were enu-
merated. The concentration that is necessary to inhibit
50% of HSV replication (IC50) compared to vehicle-treated
samples was calculated by sigmoidal fit analysis for
dose–response relationships using Origin software (Mi-
crocal, version 6.0; Northampton, MA).
Transfection studies
Vero cells (500,000 cells) were transfected with 1 pg
DNA/cell combined with Superfect (Qiagen, Inc.) per
9.6-cm2 well. The medium was replaced after 6 h.
Twenty-four hours posttransfection, supernatants were
harvested and assayed for IFN content. The cells were
subsequently infected with HSV-1 at a m.o.i. of 0.1. Me-
dium was replaced after 1 h p.i. with fresh culture me-
dium. Twenty-four or 48 h p.i. the supernatant was col-
lected and assayed for viral titers by plaque assay using
Vero cells. In one experiment, transfected, infected cells
underwent freeze–thaw three times (24 or 48 h p.i.) and
viral titers were determined in the lysates by plaque
assay.
IFN bioassay
Collected supernatants from transfected cell cultures
were clarified by centrifugation (10,000 g, 5 min). Hep-2
cells were incubated in duplicate for 24 h with serial
dilutions of the supernatants and subsequently infected
with EMCV at a m.o.i. of 0.05. When the cytopathic effect
in the control wells was maximal (between 32 and 36 h
p.i.), plates were stained with crystal violet. In each
assay, standards with rHuIFN-2 and - (PBL Biomedical
Laboratories) were used. The standards themselves
were calibrated against WHO International Standard IFN
(Braton Biotech, Inc., Gaithersburg, MD). Fifty percent
inhibition of CPE was typically equivalent to 1 U/ml for
IFN-2 and IFN- interassay variance 1.2  0.78 U/ml,
n  10. The incubation of supernatants with anti-human
IFN- and anti-human IFN- antibodies (NIAID Refer-
ence Reagent Repository, Braton Biotech, Inc.) for 1 h at
room temperature completely neutralized the protective
effect. Lowering the pH to 2 in the supernatants for 1 h
with subsequent freeze–thaw at 20°C and reestablish-
ing the pH back to 7 did not reduce the protective effect
in the bioassays (data not shown).
IFN ELISA
The amount of immunoreactive IFN protein secreted
into the supernatants was quantitated by ELISA (PBL
Biomedical Laboratories) in duplicate according to the
manufacturer’s protocol. The sensitivity range of the
IFN- ELISA was 10–5000 pg/ml and for the IFN- ELISA
125–5000 pg/ml.
Western blot analysis
Twenty-four hours posttransfection, total cell protein
was harvested following disruption of cells in SDS-con-
taining lysis buffer supplemented with a cocktail of
EDTA-free protease inhibitors (Boehringer Mannheim
GmbH, Mannheim, Germany) and 1 mM sodium or-
thovanadate (Sigma, St. Louis, MO). Protein was quanti-
tated with the BCA Protein Assay Reagent (Pierce, Rock-
ville, IL). Total cell protein (15 g) was electrophoresed
on 7.5% sodium dodecyl sulfate polyacrylamide gels (Cri-
terion precast gels; Bio-Rad, Hercules, CA) and trans-
ferred by semidry blotting onto PVDF membranes (Bio-
Rad). The membranes were blocked with 5% dry milk
overnight at 4°C and incubated with a polyclonal anti-
HSV-1 gB-specific Ab, a polyclonal anti-HSV Ab (DAKO,
Carpinteria, CA), a polyclonal anti-STAT1 p91/p84 Ab
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA), or a
polyclonal phospho-STAT1 (Y701) Ab (New England Bio-
labs, Berverly, MA) for 2 h at room temperature on a
shaking platform. The primary antibody was detected via
an anti-rabbit Ab coupled with horseradish peroxidase
(Santa Cruz) followed by detection using chemilumines-
cence detection reagents (Pierce). The resultant blots
were analyzed using the Bio-Rad 1000 image documen-
tation system and software (Quantity One 4.0.3; Bio-Rad).
RT-PCR
To determine the effect of cells transfected with the
type I IFN transgenes on selective viral and cellular gene
expression, RNA was isolated at 6 and 10 h p.i. RNA was
extracted in Ultraspect RNA isolation reagent (Biotecx,
Inc., Houston, TX). First-strand cDNA was synthesized
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using avian myoblastosis virus reverse transcriptase
(Promega, Madison, WI). PCR was performed in an Eri-
comp delta cycler (Ericomp, San Diego, CA). PCR for
GAPDH, ICP27, TK, viral protein (VP) 16, HuPKR, and
HuOAS was performed in a 50-l reaction volume con-
taining 100 ng cDNA. Primers and PCR parameters for
GAPDH, ICP27, TK, and VP16 were used as previously
described (Noisakran et al., 1999). Primers for HuPKR
were 5-CCTGTCCTCTGGTTCTTTTGC-3 (sense) and
5-TACTTCACGCTCCGCCTTC-3 (antisense) and for
HuOAS 5-GAAATACCCCAGCCAAATCTC-3 (sense)
and 5-TCACGGAAAATGCTCTCTCTC-3 (antisense).
PCR conditions for these primers were an initial dena-
turing step for 5 min at 95°C followed by 28–30 cycles at
95°C for 1 min, 60°C for 1 min, and 72°C for 2 min. PCR
products were visualized in ethidium bromide-stained,
1% agarose gels and bands were analyzed using the
Bio-Rad 1000 image documentation system and software
(Quantity One 4.0.3; Bio-Rad).
Semiquantitative real-time PCR for viral genes
Total cell RNA was isolated at 6 and 10 h p.i. in
Ultraspect RNA isolation reagent (Biotecx, Inc.) accord-
ing to the manufacturer’s protocol. Before the reverse
transcription step, DNA contamination was removed us-
ing deoxyribonuclease I according to the manufacturer’s
protocol (GIBCO BRL). First-strand cDNA was synthe-
sized using avian myoblastosis virus reverse transcrip-
tase (Promega) and an oligonucleotide dT primer (Pro-
mega). Real-time PCR was carried out in 96-well PCR
plates (Bio-Rad) using a Bio-Rad iCycler. Real-time PCR
conditions for all primers included an initial denaturing
step for 3 min at 95°C followed by 30 cycles at 95°C for
10 s and annealing/elongation at 61°C for 35 s. Each
reaction contained 45 l of PCR Platinum SuperMix
(GIBCO BRL) and SYBRgreen I (Molecular Probes, Eu-
gene, OR) at a final dilution of 1:100,000. MgCl2 was
supplemented as indicated with the primer sequences.
During the optimization procedures of the primers, 1%
agarose gel analysis verified the amplification of one
product of the predicted size with no primer–dimer
bands. The absence of primer–dimer formation for each
oligonucleotide set was also validated by establishing
the melt curve profile and determining a single amplicon
for each primer pair. The PCR results were analyzed on
the iCycler Software (version 2.3) and threshold cycles
were determined as follows. After subtracting the back-
ground fluorescence for each sample, the threshold flu-
orescence for each gene was determined at that point at
which the relative light units reached a level of more than
10 standard deviations above the baseline relative light
units. At 40 cycles, the primers-only control did not give
a signal above the threshold. At 35 cycles the primers
with uninfected cells did not give a signal above the
threshold. The semiquantitative comparison between
samples was calculated as follows.
The data were normalized by subtracting the differ-
ence of the threshold cycles (C T) between the gene of
interest (GOI C T) and the “housekeeping” gene GAPDH
C T (GOI C T  GAPDH C T  C T) for each sample. The
C T was then compared to the expression levels of the
vector control sample (sample C T  vector C T). To
determine the relative enhanced expression of the gene
of interest the following calculation was made: fold
change  2∧ [sample C T  vector C T]. If the differ-
ence (sample C T  vector C T) was a positive value
then it was calculated as fold change1/2∧ [sample
C T  vector C T] in order to get a negative value
expressing the relative suppression of the gene of inter-
est. Oligonucleotide sequences for the targeted genes
include the following: GAPDH, 5-GAATCTACTG-
GCGTCTTCACC-3 and 5-GTCATGAGCCCTTCCAC-
GATGC-3 (2 mMMgCl2); ICP27, 5-TGACGCCGAGACCA-
GAC-3 and 5-GGCAAAAGTGCGATAGAGG-3 (3 mM
MgCl2); TK, 5-AAACCACCACCACGCAAC-3 and 5-
ACACCCGCCAGTAAGTCATC-3 (3 mM MgCl2); and gB,
5-CGTTTCGCAGGTGTGGTTC-3 and 5-ATGTCG-
GTCTCGTGGTCG-3 (3 mM MgCl2).
Cell cycle analysis with propidium iodide and flow
cytometry
Vero cells were plated, transfected, and infected with
HSV-1 as described above at an m.o.i. of 1. Cells were
trypsinized and fixed in 100% ethanol and incubated with
50 g/ml propidium iodide, 1 mg/ml RNase A, and 0.1%
NP-40 (Sigma Chemical Co.) in Ca2- and Mg2-free PBS
for 20 min. Twenty thousand events were analyzed on a
FACScalibur (Becton–Dickinson, Mountain View, CA) and
the data were analyzed using WinMDI 2.8 software.
Statistics
Analysis of normally distributed data was carried out
by one-way ANOVA and a post hoc multiple comparison
test (Scheffe´ or Tukey’s t test) to determine significance
(P  0.05). Analysis of nonparametric data was carried
out by Mann–Whitney U test to determine significance
(P  0.05). All statistical analysis was performed using
the GBSTAT program Version 3.0 (Dynamic Microsys-
tems, Silver Spring, MD).
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